Identification and structure-activity relationships of a new series of Melanocortin-4 receptor antagonists.
The identification and optimization of a series of acylguanidine-based melanocortin-4 receptor antagonists is discussed.
Vos
Tricia J
TJ
Millennium Pharmaceuticals, Inc. 40 Landsdowne St. Cambridge, MA 02139, USA. tricia.vos@mpi.com
Balani
Suresh
S
Blackburn
Christopher
C
Chau
Ryan W
RW
Danca
M Diana
MD
Drabic
Stacey V
SV
Farrer
Cheryl A
CA
Patane
Michael A
MA
Stroud
Stephen G
SG
Yowe
David L
DL
Claiborne
Christopher F
CF
D000818:Animals; D001665:Binding Sites; D001921:Brain / Q000378:metabolism; D019791:Guanidine / Q000031:analogs & derivatives / Q000737:chemistry* / Q000494:pharmacology; D020128:Inhibitory Concentration 50; D051379:Mice; D010949:Plasma / Q000378:metabolism; D044105:Receptor, Melanocortin, Type 4 / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship; D013438:Sulfhydryl Compounds / Q000737:chemistry* / Q000494:pharmacology; D013997:Time Factors
D044105:Receptor, Melanocortin, Type 4; D013438:Sulfhydryl Compounds; D019791:Guanidine